Cristiane Bergerot, Head of the Department of Psycho-Oncology at Grupo Oncoclínicas, Brazil, posted on X:
“Does adding irinotecan + temozolomide improve outcomes in newly diagnosed Ewing sarcoma?
This phase II trial did not exceed the predefined 4-year EFS benchmark in localized disease.”
Title: Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator-Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Authors: Emily Slotkin, Audrey Mauguen, Neerav Shukla, Heather Magnan, Anita Bowman, Julia Glade Bender, Filemon Dela Cruz, Gregory Nalesnik, Michael Ortiz, Tara O’Donohue, Michael Kinnaman, William Tap, Jovana Pavisic, Srikanth Ambati, Alexander Chou, Narasimhan Agaram, Cristina Antonescu, Meera Hameed, Marc Ladanyi, Konstantinos Linos, Neeta Pandit-Taskar, Anita Price, Gerald Behr, Damon Reed, Leonard Wexler, Paul Meyers
Other articles featuring Cristiane Bergerot on OncoDaily.
